| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 02/27/2003 | US20030040536 For therapy of disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease |
| 02/27/2003 | US20030040535 Tetrazole compounds as thyroid receptor ligands |
| 02/27/2003 | US20030040533 For use as hypoglycaemic and hypolipidaemic agents |
| 02/27/2003 | US20030040531 For therapy and prophylaxis of reperfusion injury |
| 02/27/2003 | US20030040523 Pyrimidine compounds and their use as modulators of chemokine receptor activity |
| 02/27/2003 | US20030040517 For use in therapy of pain, fever, inflammation of a variety of conditions and diseases |
| 02/27/2003 | US20030040513 P2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases |
| 02/27/2003 | US20030040512 Pharmaceutical composition with protective action against oxidative/toxic substances, especially cardiotoxic substances |
| 02/27/2003 | US20030040510 Selective estrogen receptor modulators in combination with estrogens |
| 02/27/2003 | US20030040509 Methods and compositions for treating diseases associated with excesses in ACE |
| 02/27/2003 | US20030040508 Altering the conformational equilibrium of the A- ring of a 1 alpha -hydroxylated vitamin D compound to favor a chair conformation for A-ring that presents the 1 alpha-hydroxyl in an axial orientation |
| 02/27/2003 | US20030040484 Administering a therapeutically-effective amount of an angiotensin converting enzyme inhibitor and administering an aldosterone antagonist to reduce the death rate or the number of non-fatal hospitalizations |
| 02/27/2003 | US20030040044 Anti-dual integrin antibodies, compositions, methods and uses |
| 02/27/2003 | US20030039984 Sequences upstream of the CARP gene, vectors containing them and uses thereof |
| 02/27/2003 | US20030039677 Apparatus and method for delivering compounds to a living organism |
| 02/27/2003 | US20030039656 Modified reoviral therapy |
| 02/27/2003 | US20030039654 Amino acid sequence of parathyroid hormone/parathyroid hormone related protein modulating domains and a vehicle for to stimulate renal calcium reabsorption |
| 02/27/2003 | US20030039629 Espression enhancer for protein synthesis inhibitory genes |
| 02/27/2003 | US20030039626 Fat-binding polymers |
| 02/27/2003 | CA2459692A1 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| 02/27/2003 | CA2458648A1 Secreted proteins |
| 02/27/2003 | CA2458643A1 Nucleic-acid associated proteins |
| 02/27/2003 | CA2458625A1 Transporters and ion channels |
| 02/27/2003 | CA2458068A1 Methods and compositions for treating apoptosis associated disorders |
| 02/27/2003 | CA2457789A1 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides |
| 02/27/2003 | CA2457783A1 Oligonucleotide compositions and their use to induce apoptosis |
| 02/27/2003 | CA2457644A1 Sesquiterpenoid derivatives having adipocyte differentiation inhibitory effect |
| 02/27/2003 | CA2457611A1 Novel molecular target for neurotoxicity |
| 02/27/2003 | CA2457482A1 5-amidino-n-(2-aminophenethyl)-2-hydroxybenzenesulfonamide derivative, medicinal composition containing the same, and intermediate therefor |
| 02/27/2003 | CA2457461A1 Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b |
| 02/27/2003 | CA2457453A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine |
| 02/27/2003 | CA2457452A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| 02/27/2003 | CA2457356A1 Canine cardiac diet |
| 02/27/2003 | CA2457164A1 Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival of cells |
| 02/27/2003 | CA2457142A1 Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders |
| 02/27/2003 | CA2457041A1 Novel combination |
| 02/27/2003 | CA2457037A1 Aminoalkyl-substituted aromatic bicyclic compounds, method for the production thereof and their use as medicaments |
| 02/27/2003 | CA2457033A1 A medecine for cardiac failure |
| 02/27/2003 | CA2456988A1 Gas microsphere liposome composites |
| 02/27/2003 | CA2456985A1 2h-phthalazin-1-ones and methods for use thereof |
| 02/27/2003 | CA2456868A1 Inhibitors of polyq-aggregation |
| 02/27/2003 | CA2456841A1 Cyclohexyl and piperidine diamine derivatives useful as activated blood coagulation factor x inhibitors |
| 02/27/2003 | CA2456743A1 Tocopherol enriched compositions and amelioration of inflammatory symptoms |
| 02/27/2003 | CA2456150A1 Selective estrogen receptor modulators |
| 02/27/2003 | CA2453647A1 1-alkyl 0r 1-cycloalkyltriazolo¬4,3-a|quinazolin-5-ones as phosphodiesterase inhibitors |
| 02/27/2003 | CA2423025A1 New dipeptidyl peptidase iv inhibitors and their uses for lowering blood pressure levels |
| 02/26/2003 | WO2002020467A1 Novel crystals of n-hydroxy-2(s)-methyl-5-ethoxymethoxy -4(s)-[n-(4-phenoxyphenylcarbonyl)amino]pentanamide, process for their production and medicines containing the crystals as the active ingredient |
| 02/26/2003 | EP1285922A1 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors |
| 02/26/2003 | EP1285914A1 Nr1h4 nuclear receptor binding compounds |
| 02/26/2003 | EP1285908A1 Substituted phenylpropionic acid derivatives |
| 02/26/2003 | EP1285657A2 Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
| 02/26/2003 | EP1285655A1 Stabilized pharmaceutical compositions containing calcium channel blockers |
| 02/26/2003 | EP1285654A1 Autonomic controlling agents and health drinks and foods |
| 02/26/2003 | EP1285652A1 Novel fatty acid analogues for the treatment of hypertension |
| 02/26/2003 | EP1285650A1 Method and compositions for inhibiting arteriosclerosis |
| 02/26/2003 | EP1285269A2 Lipid uptake assays |
| 02/26/2003 | EP1285087A2 Enzymatic assays for screening anti-cancer agents |
| 02/26/2003 | EP1285074A1 Rh116 polypeptides and its fragments and polynucleotides encoding said polypeptides and therapeutic uses |
| 02/26/2003 | EP1285071A2 Novel dual oxidases as mitogenic and endocrine regulators |
| 02/26/2003 | EP1285063A1 Anti-angiogenic polypeptides |
| 02/26/2003 | EP1285002A2 REGULATING LIPID LEVELS VIA THE i ZMAX1 /i OR i HBM /i GENE |
| 02/26/2003 | EP1285001A1 Methods for identifying modulators of the interaction between lap (latency associated peptide) and integrin alpha.v.beta.3 and medical use thereof |
| 02/26/2003 | EP1285000A2 Use of adnf for enhancing learning and memory |
| 02/26/2003 | EP1284974A2 Triazolyl tropane derivatives as ccr5 modulators |
| 02/26/2003 | EP1284973A2 Inhibitors of alpha l beta 2 mediated cell adhesion |
| 02/26/2003 | EP1284963A1 Novel calcium receptor active molecules and method for preparing same |
| 02/26/2003 | EP1284961A1 Glycinamides |
| 02/26/2003 | EP1284959A1 Compounds for modulating the rage receptor |
| 02/26/2003 | EP1284958A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoidane derivatives |
| 02/26/2003 | EP1284957A1 Purification method of n-(1(s)-ethoxycarbonyl-3-phenylpropyl)-l-alanine |
| 02/26/2003 | EP1284956A1 Il-8 receptor antagonists |
| 02/26/2003 | EP1284753A2 Combination of growth hormone secretagogues and antidepressants |
| 02/26/2003 | EP1284749A2 Use of hyaluronidase for preventing and treating cardio vascular diseases |
| 02/26/2003 | EP1284747A2 Compositions and methods for achieving immune suppression |
| 02/26/2003 | EP1284739A1 Composition and method for intervening neuronal death using sulfasalazine |
| 02/26/2003 | EP1284734A1 Protein kinase inhibitors |
| 02/26/2003 | EP1284733A1 Novel processes for preparing torsemide intermediate |
| 02/26/2003 | EP1284730A1 Aralkyl ester soft drugs |
| 02/26/2003 | EP1284728A1 Pharmaceuticals for treating obesity |
| 02/26/2003 | EP1284727A1 Intracorporeal medicaments for photodynamic treatment of disease |
| 02/26/2003 | EP1284724A1 Method of preparing alkylated salicylamides via a dicarboxylate intermediate |
| 02/26/2003 | EP1284723A1 Compositions and therapies for hyperlipidaemia-associated disorders |
| 02/26/2003 | EP1284717A1 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base |
| 02/26/2003 | EP1150976B1 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase |
| 02/26/2003 | EP1128837B1 Medicament for preventing and reversing atherosclerosis in mammals |
| 02/26/2003 | EP1042297B1 Carboxyl acid substituted heterocycles as metalloproteinase inhibitors |
| 02/26/2003 | EP0969827B1 Mixture of primary fatty acids obtained from sugar cane wax |
| 02/26/2003 | EP0929571B1 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators |
| 02/26/2003 | EP0920431B1 Thienopyrimidines |
| 02/26/2003 | EP0754040B1 Rapamycin derivatives |
| 02/26/2003 | CN1399678A Human Enzymes of metalloprotease family |
| 02/26/2003 | CN1399644A Novel human G-Protein coupled receptor |
| 02/26/2003 | CN1399639A New oxabispidine compound useful in treatment of cardiac arrhythmias |
| 02/26/2003 | CN1399638A Indoloazepines as vasopressin receptor antagonists |
| 02/26/2003 | CN1399636A Adenosine receptor antagonists and methods of making and using the same |
| 02/26/2003 | CN1399633A 嘧啶衍生物 Pyrimidine derivatives |
| 02/26/2003 | CN1399632A Pyrimidine derivatives, process for preparing the derivatives and drugs containing the same as active ingredient |
| 02/26/2003 | CN1399631A Novel hydantoin, thiohydantoin, pyrimidinedione and thioxopyrimidinone derivatives, preparation method and use as medicines |
| 02/26/2003 | CN1399630A Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and the use thereof as medicaments |
| 02/26/2003 | CN1399622A Triphenylalkene derivatives and their use as selective estrogen receptor modulators |